man-user-icon Client Login Portal
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    Labaton Sucharow
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Contact Us
    • Knowledge Network
    • Client Login
    • Search
    • addthis
    • link : Client Login
    • knowledge network
    Labaton Sucharow
    • Ongoing Cases
    • Settled | Resolved Cases
    • Featured Cases
      • Securities
      • Antitrust
      • Derivative
      • Mergers & Acquisitions
      • REITs and Limited Partnerships

    In re Aggrenox Antitrust Litigation

    Updated: July 20, 2018

    Status: Ongoing Case

    On June 12, 2014, Labaton Sucharow filed a class action complaint on behalf of consumers and third-party payors (“end-payors”) who purchased, paid for, or were reimbursed for prescriptions of combination aspirin and extended-release dipyridamole, a drug manufactured by global pharmaceutical company Boehringer Ingelheim under the brand name Aggrenox. Aggrenox is typically used to lower the risk of stroke in people who have suffered a transient ischemic attack (mini-stroke) or stoke due to a blood clot.

    The plaintiffs alleged that, absent the Aggrenox pay-for-delay agreements, generic versions of Aggrenox would have been on the market as early as August 14, 2009. This pay-for-delay agreement caused plaintiffs and the class to continue paying supracompetitive prices for Aggrenox throughout the class period, beginning August 14, 2009.

    The court denied in part the defendants’ motions to dismiss the end-payor plaintiffs’ claims in August 2016. The court also ruled in August 2016 that the market is limited to the market for Aggrenox and its generic equivalents. On July 20, 2018, the court gave final approval to a $54 million settlement between all defendants the end-payor plaintiffs.

    Labaton Sucharow served as class counsel in this matter.

    The case is In re Aggrenox Antitrust Litigation. The plaintiff is Pipefitters Union Local No. 537 Health & Welfare Fund. The defendant is Boehringer Ingelheim Pharma GmbH.

    Background
    Aggrenox was a core drug for Boehringer Ingelheim, generating several hundred million dollars a year. Generic manufacturer Barr Pharmaceuticals (now Teva) wanted to enter the market with lower-priced generic alternatives to the brand-named drug, which would provide significant cost savings to consumers. Barr challenged the validity and enforceability of the patent covering Aggrenox. The plaintiff alleges that rather than risk a court determination that the Aggrenox patent was invalid or unenforceable, Boehringer agreed to pay Barr with up to $120 million in one-time and annual royalty payments for co-promotional services relating to the sale of Aggrenox in exchange for Barr agreeing to abandon its patent challenge and refrain from launching a generic version of Aggrenox until at least July 2015. This agreement substantially delayed entry of low-cost generic alternatives into the market, thereby reducing competitive options to consumers and maintaining high Aggrenox prices. The payment agreement that the defendants entered into are typically referred to as reverse payment or pay-for-delay agreements.

    Useful Links

    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Center

    Our Locations

    footer-list-map_icon New York
    140 Broadway
    New York, NY 10005
    212-907-0700

    footer-list-map_icon Delaware
    300 Delaware Avenue, Suite 1340
    Wilmington, DE 19801
    302-573-2540

    Useful Links

    footer-list-map_icon Washington, D.C.
    1050 Connecticut Avenue, NW, Suite 500
    Washington, D.C. 20036
    202-772-1880

    Stay Connected

    • Facebook
    • Twitter
    • LinkedIn
    Labaton Sucharow
    • Attorney Advertising Disclaimer
    • Privacy Policy
    • labaton.com
    • Labaton Sucharow All Rights Reserved 2019

    Attorney Advertising Disclaimer

    The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.